help button home button Am J Pathol ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Related articles in Am J Pathol
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nijmeijer, R.
Right arrow Articles by Hack, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nijmeijer, R.
Right arrow Articles by Hack, C. E.
(American Journal of Pathology. 2003;163:269-275.)
© 2003 American Society for Investigative Pathology

C-Reactive Protein Activates Complement in Infarcted Human Myocardium

Remco Nijmeijer*{dagger}{ddagger}§, Wim K. Lagrand*{ddagger}, Yvonne T. P. Lubbers§, Cees A. Visser*{ddagger}, Chris J. L. M. Meijer{dagger}, Hans W. M. Niessen*{dagger} and C. Erik Hack*§

From the Institute for Cardiovascular Research* and the Departments of Pathology,{dagger} Cardiology,{ddagger} and Clinical Chemistry, Vrije Universiteit Medical Center, Amsterdam; and the Department of Immunopathology,§ Sanquin Research at the Central Laboratory of the Blood Transfusion Service, Amsterdam, The Netherlands

Circulating levels of C-reactive protein (CRP) constitute a cardiovascular risk marker. Immunohistochemical studies have revealed co-localization of CRP and activated complement in human infarcted myocardium suggesting CRP to enhance inflammation in ischemic myocardium by inducing local complement activation. The aim was to establish whether CRP activates complement in infarcted human myocardium and to assess the relationship between this activation and the duration of infarction. Myocardial tissue samples from 56 patients that had died from acute myocardial infarction were evaluated. Specimens were taken from infarcted as well as noninfarcted sites of the heart. CRP-mediated complement activation was assessed by immunohistochemistry and by measuring levels of complement, CRP, and CRP-complement complexes, specific markers for CRP-mediated activation, in homogenates of the heart. Infarctions of 12 hours to 5 days had significantly more extensive depositions of complement and CRP and contained significantly more CRP, activated complement, and CRP-complement complexes than infarctions that were less than 12 hours old. Levels of CRP complexes correlated significantly with CRP and complement concentrations in the infarctions, as well as with the extent of complement and CRP depositions as measured via immunohistochemistry. Specific activation products of CRP-mediated activation of complement are increased in infarcts of more than 12 hours in duration and correlate with the extent of complement depositions. Hence, CRP seems to enhance local inflammatory reactions ensuing in human myocardial infarcts of more than 12 hours duration.


Related articles in Am J Pathol:

This Month in AJP

Am J Pathol 2003 163: 1-2. [Full Text]  



This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
S. Norja, L. Nuutila, P. J Karhunen, and S. Goebeler
C-reactive protein in vulnerable coronary plaques
J. Clin. Pathol., May 1, 2007; 60(5): 545 - 548.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
E. A. Booth, N. R. Obeid, and B. R. Lucchesi
Activation of estrogen receptor-{alpha} protects the in vivo rabbit heart from ischemia-reperfusion injury
Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2039 - H2047.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P. Theroux, P. W. Armstrong, K. W. Mahaffey, J. S. Hochman, K. J. Malloy, S. Rollins, J. C. Nicolau, J. Lavoie, T. M. Luong, J. Burchenal, et al.
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial
Eur. Heart J., October 1, 2005; 26(19): 1964 - 1970.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. E. Fiane, T. Ueland, S. Simonsen, H. Scott, K. Endresen, L. Gullestad, O. R. Geiran, G. Haraldsen, L. Heggelund, A. K. Andreassen, et al.
Low mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation
Eur. Heart J., August 2, 2005; 26(16): 1660 - 1665.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. A. Lauver, S. F. Lockwood, and B. R. Lucchesi
Disodium Disuccinate Astaxanthin (Cardax) Attenuates Complement Activation and Reduces Myocardial Injury following Ischemia/Reperfusion
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 686 - 692.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
D. C. W. Poland, J.-J. G. Vallejo, H. W. M. Niessen, R. Nijmeyer, J. Calafat, C. E. Hack, B. Van het Hof, and W. Van Dijk
Activated human PMN synthesize and release a strongly fucosylated glycoform of {alpha}1-acid glycoprotein, which is transiently deposited in human myocardial infarction
J. Leukoc. Biol., August 1, 2005; 78(2): 453 - 461.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
M. Satoh, M. Nakamura, T. Akatsu, Y. Shimoda, I. Segawa, and K. Hiramori
C-reactive protein co-expresses with tumor necrosis factor-{alpha} in the myocardium in human dilated cardiomyopathy
Eur J Heart Fail, August 1, 2005; 7(5): 748 - 754.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. Trion, M.P.M. de Maat, J.W. Jukema, A. van der Laarse, M.C. Maas, E.H. Offerman, L.M. Havekes, A.J. Szalai, H.M.G. Princen, and J.J. Emeis
No Effect of C-Reactive Protein on Early Atherosclerosis Development in Apolipoprotein E*3-Leiden/Human C-Reactive Protein Transgenic Mice
Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1635 - 1640.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
M. Di Napoli, M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H. C.A. Emsley, S. Forconi, S. J. Hopkins, L. Masotti, et al.
Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke: A Statement for Health Care Professionals From the CRP Pooling Project Members
Stroke, June 1, 2005; 36(6): 1316 - 1329.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
P A J Krijnen, C Ciurana, T Cramer, T Hazes, C J L M Meijer, C A Visser, H W M Niessen, and C E Hack
IgM colocalises with complement and C reactive protein in infarcted human myocardium
J. Clin. Pathol., April 1, 2005; 58(4): 382 - 388.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
A. Chait, C. Y. Han, J. F. Oram, and J. W. Heinecke
Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?
J. Lipid Res., March 1, 2005; 46(3): 389 - 403.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. A. Lauver, E. A. Booth, A. J. White, E. Poradosu, and B. R. Lucchesi
Sulodexide Attenuates Myocardial Ischemia/Reperfusion Injury and the Deposition of C-Reactive Protein in Areas of Infarction without Affecting Hemostasis
J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 794 - 800.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society for Investigative Pathology.